According to The Insight Partners, the Drug-Eluting Balloon Market size is expected to reach US$ 3,663.64 million by 2031; it is estimated to record a CAGR of 17.5% till 2031.
Drug-Eluting Balloon Market Size, Share, Trends, Analysis, and Forecast by 2031
– The drug-eluting balloon market is projected to reach US$ 3,663.64 million by 2031, registering a CAGR of 17.5%. Market growth is supported by rising cardiovascular disease incidence, increasing preference for minimally invasive procedures, and technological advancements in drug-coated balloon systems.
Drug-Eluting Balloon Market Overview
Drug-eluting balloons are specialized medical devices designed to deliver therapeutic drugs directly to the inner walls of blood vessels during minimally invasive vascular procedures.
Download Sample PDF – https://www.theinsightpartners.com/sample/TIPRE00003085
These devices typically feature a balloon catheter coated with an antiproliferative drug that is transferred to the vessel wall when the balloon is inflated. The drug helps inhibit excessive cell growth and reduce the risk of restenosis, which is the re-narrowing of a blood vessel following treatment.
Drug-eluting balloons are increasingly used in the treatment of coronary artery disease and peripheral artery disease. They offer an alternative or complementary approach to conventional balloon angioplasty and drug-eluting stents in selected clinical situations. By delivering medication directly to the treatment site without necessarily leaving a permanent implant, these devices can be particularly useful in certain cases involving in-stent restenosis and peripheral vascular lesions.
The market is gaining momentum as healthcare providers seek treatment options that improve procedural outcomes while limiting complications associated with recurrent vessel narrowing. Developments in drug-coating formulations, balloon materials, catheter design, and drug-transfer mechanisms are improving device performance and expanding potential clinical applications. However, treatment selection depends on the patient’s condition, lesion characteristics, clinical evidence, and applicable medical guidelines.
Key Players in the Drug-Eluting Balloon Market
Several medical technology companies participate in the drug-eluting balloon market through the development, manufacture, and commercialization of vascular intervention devices. Key players include:
- Medtronic plc
- Becton, Dickinson and Company
- Boston Scientific Corporation
- Cook Medical
- B. Braun Melsungen AG
- Koninklijke Philips N.V.
- Opto Circuits Limited
- Terumo Corporation
- Biotronik SE & Co. KG
- Innvolution Healthcare Pvt. Ltd.
These companies compete through product innovation, clinical research, strategic collaborations, regulatory approvals, and expansion into new geographic markets. Their ability to demonstrate device safety, effectiveness, and reliable drug delivery is important for strengthening market presence. Product portfolios and commercial participation may vary by region and clinical application.
Drug-Eluting Balloon Market Growth Drivers
Increasing Prevalence of Cardiovascular Diseases
The rising prevalence of cardiovascular diseases is a major factor driving the drug-eluting balloon market. Coronary artery disease and peripheral artery disease can restrict blood flow and require interventional treatment to restore circulation. Drug-eluting balloons deliver medication directly to the treated vessel, helping reduce excessive tissue growth and the risk of restenosis. The growing demand for effective vascular interventions is encouraging healthcare providers to consider these devices for appropriate patients.
Growing Product Innovations and Regulatory Approvals
Technological advancements in drug formulations, coating technologies, and catheter design are supporting market expansion. Manufacturers are developing devices intended to improve drug transfer, maintain coating stability, and enhance treatment outcomes. Regulatory approvals are also helping expand the range of available treatment options. For example, Boston Scientific received US Food and Drug Administration approval for its AGENT Drug-Coated Balloon in March 2024 to treat coronary in-stent restenosis. Such developments demonstrate the expanding role of drug-coated balloons in vascular interventions.
Rising Preference for Minimally Invasive Procedures
The increasing preference for minimally invasive treatments is another important growth driver. Balloon-based interventions can reduce the need for more invasive surgical procedures in suitable patients and may support shorter recovery periods. Drug-eluting balloons can also provide localized drug delivery without necessarily leaving a permanent implant at the treatment site. These characteristics are encouraging clinical interest in drug-eluting balloon technologies for selected coronary and peripheral vascular conditions.
Drug-Eluting Balloon Market Trends and Opportunities
A key trend in the market is the expansion of drug-eluting balloon applications beyond traditional coronary interventions. Manufacturers and researchers are exploring their use across different vascular conditions, including peripheral artery disease. Improvements in coating technologies and drug delivery systems are also creating opportunities to enhance treatment performance.
Another emerging area is the development of combination treatment strategies. Depending on the clinical indication, physicians may consider drug-eluting balloons alongside other interventional approaches. Growing clinical research, product approvals, and partnerships between medical device manufacturers and healthcare institutions may further support adoption.
Emerging economies also offer growth opportunities as healthcare infrastructure improves and access to advanced cardiovascular procedures increases. Nevertheless, manufacturers must address device costs, regulatory requirements, clinical evidence expectations, and reimbursement differences to achieve broader adoption.
Regional Analysis
The drug-eluting balloon market is analyzed across North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Regional growth varies according to cardiovascular disease prevalence, healthcare infrastructure, regulatory approvals, reimbursement policies, and access to interventional cardiology services.
North America held the largest regional position in the market, supported by advanced medical facilities, established medical device companies, and increasing adoption of innovative vascular treatments. The US is a key contributor to regional demand, particularly as new product approvals expand treatment options.
Europe represents another important market, supported by established healthcare systems, clinical expertise, and the availability of advanced vascular intervention technologies. Demand is influenced by clinical evidence, product availability, and country-specific regulatory and reimbursement frameworks.
Asia Pacific offers opportunities for market expansion as healthcare investment increases, cardiovascular disease management receives greater attention, and access to minimally invasive procedures improves. Countries such as China, India, and Japan are important markets to monitor. South and Central America and the Middle East and Africa may also experience growth as specialized cardiovascular services and access to advanced medical devices expand.
Drug-Eluting Balloon Market Challenges
Despite favorable growth prospects, the market faces challenges related to stringent regulatory requirements, high device and procedure costs, and differences in reimbursement coverage. Manufacturers must demonstrate product safety and effectiveness through appropriate clinical evidence before expanding into new applications or geographic markets.
Furthermore, treatment decisions depend on the type of vascular disease, lesion characteristics, and individual patient needs. Competition from alternative vascular interventions, including conventional angioplasty and drug-eluting stents, can also influence adoption. Addressing these challenges through clinical research, cost management, and continued product innovation will remain important for market participants.
Future Outlook
The drug-eluting balloon market is expected to present opportunities through 2031 as cardiovascular disease management advances and demand for minimally invasive vascular interventions increases. Continued research into drug delivery, coating performance, and new clinical applications may strengthen the role of these devices in interventional care. Product development, regulatory progress, and wider access to advanced treatment facilities will influence the pace of adoption across regions.
Get Premium Market Research Report Here: https://www.theinsightpartners.com/buy/TIPRE00003085
Companies that prioritize clinical evidence, product quality, strategic partnerships, and geographic expansion are positioned to pursue emerging opportunities. However, long-term growth will depend on demonstrating clinical value, addressing cost barriers, and meeting the evolving needs of healthcare providers and patients.
About Us
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients meet their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals and Materials.
Contact Us
Ankit Mathur | The Insight Partners
E-mail: [email protected]
Phone: +1-646-491-9876
Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish